We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+33.14%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$7.1B
AUM Growth
+$1.15B
Cap. Flow
-$108M
Cap. Flow %
-1.52%
Top 10 Hldgs %
31.14%
Holding
166
New
24
Increased
29
Reduced
28
Closed
31

Top Buys

Rank Stock Value
1
BNR
Burning Rock Biotech
BNR
+$130M
2
RPTX
Repare Therapeutics
RPTX
+$110M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$93.3M
4
BIIB icon
Biogen
BIIB
+$70.8M
5
TBPH icon
Theravance Biopharma
TBPH
+$60.2M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$237M
2
PFE icon
Pfizer
PFE
+$98.3M
3
GILD icon
Gilead Sciences
GILD
+$98M
4
ALEC icon
Alector
ALEC
+$64.9M
5
HCA icon
HCA Healthcare
HCA
+$63.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.96%
2 Financials 1.61%
3 Miscellaneous 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLT
51
DELISTED
Applied Therapeutics
APLT
$44M 0.62%
1,217,678
-102,199
-8% -$4.28M
QURE icon
52
uniQure
QURE
$2.99B
$43.7M 0.61%
969,079
-14,900
-2% -$880K
TMO icon
53
Thermo Fisher Scientific
TMO
$237B
$40M 0.56%
110,300
– –
TELA icon
54
TELA Bio
TELA
$48.9M
$39.2M 0.55%
3,027,542
– –
SYRE icon
55
Spyre Therapeutics
SYRE
$8.02B
$37.1M 0.52%
160,621
+46,000
+40% +$8.76M
PRTA icon
56
Prothena Corp
PRTA
$428M
$37.1M 0.52%
3,544,475
+642,236
+22% +$7.14M
EW icon
57
Edwards Lifesciences
EW
$49.4B
$36.7M 0.52%
530,400
– –
ALPN
58
DELISTED
Alpine Immune Sciences Inc
ALPN
$35.6M 0.5%
3,670,955
– –
SCPH
59
DELISTED
scPharmaceuticals
SCPH
$35.3M 0.5%
4,797,148
+1,387,283
+41% +$12.2M
NSTG
60
DELISTED
NanoString Technologies, Inc.
NSTG
$35M 0.49%
1,192,400
– –
ACHC icon
61
Acadia Healthcare
ACHC
$2.55B
$34.7M 0.49%
1,380,160
– –
SLQT icon
62
SelectQuote
SLQT
$87.1M
$31.8M 0.45%
+1,255,000
New +$33.7M
XENE icon
63
Xenon Pharmaceuticals
XENE
$5.45B
$31.3M 0.44%
2,497,917
+835,105
+50% +$10.6M
HARP
64
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$30.5M 0.43%
183,570
-61,071
-25% -$9.53M
INSP icon
65
Inspire Medical Systems
INSP
$2.16B
$30.2M 0.43%
347,000
– –
PCVX icon
66
Vaxcyte
PCVX
$8.81B
$26.9M 0.38%
+850,000
New +$27.3M
IMMU
67
DELISTED
Immunomedics Inc
IMMU
$26.9M 0.38%
+757,900
New +$22.2M
SVA
68
DELISTED
Sinovac Biotech, Ltd
SVA
$25.5M 0.36%
2,839,500
– –
IQV icon
69
IQVIA
IQV
$44.4B
$24.8M 0.35%
175,000
– –
TEVA icon
70
Teva Pharmaceuticals
TEVA
$45.7B
$23.9M 0.34%
+1,935,200
New +$21.9M
FLXN
71
DELISTED
Flexion Therapeutics, Inc.
FLXN
$22.1M 0.31%
1,684,000
+1,551,000
+1,166% +$16.1M
SIBN icon
72
SI-BONE Inc
SIBN
$831M
$22M 0.31%
1,381,300
– –
NVO
73
Novo Nordisk
NVO
$188B
$21.6M 0.3%
660,000
– –
AMGN icon
74
Amgen
AMGN
$203B
$21.6M 0.3%
91,500
-13,700
-13% -$3.13M
ZYME icon
75
Zymeworks
ZYME
$1.86B
$21M 0.3%
582,302
– –
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2020 Portfolio in Review

As of Q2 2020, OrbiMed held 166 positions worth $7.1B, up 19% from $5.95B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed's Q2 2020 filing shows 24 new, 29 increased, 28 reduced and 31 closed positions. Its largest new stake was Burning Rock Biotech: 474,607 shares worth $128M. The largest sale was Ascendis Pharma A/S, an estimated $237M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials and Miscellaneous.

  • OrbiMed's largest Q2 2020 buy was Burning Rock Biotech: 474,607 shares worth $128M.
  • OrbiMed added most to Biogen in Q2 2020, an estimated $70.8M increase.
  • OrbiMed's biggest Q2 2020 reduction was Ascendis Pharma A/S, cutting an estimated $237M.
  • OrbiMed fully exited Pfizer in Q2 2020, selling an estimated $98.3M.
  • OrbiMed's ten largest holdings make up 31% of its $7.1B portfolio in Q2 2020.
  • OrbiMed opened 24 new positions and closed 31 in Q2 2020.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $7.1B.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.